Cargando…

Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients

BACKGROUND: The efficacy of nucleot(s)ide analogs (NAs) and pegylated interferon (PegIFN) combination therapy for hepatitis B e antigen–positive (HBeAg(+)) patients is still controversial. Whether PegIFN and entecavir (ETV) combination therapy could provide a greater benefit for HBeAg(+) patients wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lu, Lin, Lanyi, Zhou, Huijuan, Tang, Weiliang, Wang, Hui, Cai, Wei, Bao, Shisan, Guo, Simin, Xie, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050793/ https://www.ncbi.nlm.nih.gov/pubmed/33889654 http://dx.doi.org/10.1093/ofid/ofaa462

Ejemplares similares

Erratum to: Peginterferon and Entecavir Combination Therapy Improves Outcome of Non–Early Response Hepatitis B e Antigen–Positive Patients
por: Chen, Lu, et al.
Publicado: (2021)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B
por: Brakenhoff, Sylvia M, et al.
Publicado: (2022)

Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels
por: Zeng, Qing-Lei, et al.
Publicado: (2020)

A five years study of antiviral effect of entecavir in Chinese chronic hepatitis B patients
por: Liu, Kehui, et al.
Publicado: (2016)

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
por: Yu, Jiao, et al.
Publicado: (2022)

Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin
por: Howe, John A., et al.
Publicado: (2014)

Retracted: Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin
por: Fevery, Bart, et al.
Publicado: (2016)

Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
por: Liem, Kin Seng, et al.
Publicado: (2019)

Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure
por: Cao, Zhujun, et al.
Publicado: (2015)

Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion
por: Yang, Hui Y, et al.
Publicado: (2014)

Effects of Entecavir on Hepatitis B Virus Covalently Closed Circular DNA in Hepatitis B e Antigen-Positive Patients with Hepatitis B
por: Shi, Ming, et al.
Publicado: (2015)

Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy
por: Wang, Yun, et al.
Publicado: (2016)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study
por: Sonneveld, Milan J, et al.
Publicado: (2020)

Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis
por: Gui, Hong-Lian, et al.
Publicado: (2020)

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
por: Marcellin, Patrick, et al.
Publicado: (2012)

HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults
por: Matthews, Philippa C., et al.
Publicado: (2016)

Seroconversion of Hepatitis B Virus Surface Antigen in Chronic Hepatitis B Child Treated with Entecavir
por: Li, Dong, et al.
Publicado: (2012)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment
por: Wang, Kaifa, et al.
Publicado: (2020)

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
por: Lok, Anna S., et al.
Publicado: (2019)

Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: A pilot study
por: Du, Qing-Wei, et al.
Publicado: (2013)

Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment
por: Li, Jun, et al.
Publicado: (2023)

N‐myc and STAT interactor correlates with severity and prognosis in acute‐on‐chronic liver failure of hepatitis B virus
por: Xiong, Lifu, et al.
Publicado: (2019)

Seroconversion of Hepatitis B Envelope Antigen (HBeAg) by Entecavir in a Child with Chronic Hepatitis B
por: Hasosah, Mohammed Y., et al.
Publicado: (2012)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients
por: Chen, Liwen, et al.
Publicado: (2018)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Rong, Guanghua, et al.
Publicado: (2020)

Hepatitis B Core Antigen Expression in Hepatocytes Reflects Viral Response to Entecavir in Chronic Hepatitis B Patients
por: Lee, Jeong Guil, et al.
Publicado: (2013)

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B
por: Peng, Cheng-Yuan, et al.
Publicado: (2017)

Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma
por: Mak, Lung-Yi, et al.
Publicado: (2020)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2018)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

The role of entecavir in the treatment of chronic hepatitis B
por: Dimou, Evangelini, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_aolspidn0ehlr9r0r83v6iq1ii